

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



November 6, 2024

**National Stock Exchange of India Limited**  
**Scrip Symbol: SUNPHARMA**

**BSE Limited**  
**Scrip Code: 524715**

**Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory Order**

This is to inform that the Company has received orders passed by statutory authority. Relevant details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are provided in Annexure A.

The Company shall take appropriate action in the matter.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: [www.sunpharma.com](http://www.sunpharma.com)

Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)

CIN: L24230GJ1993PLC019050

**Annexure A****Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Sl. No.	Particulars	Information
a)	Name of the authority	Regional Director, North Western Region, Ministry of Corporate Affairs
b)	Nature and details of the action(s) taken, initiated, or order(s) passed	Adjudication Orders passed under Section 454 for alleged violations under certain provisions of the Companies Act, 2013. The penalty imposed on the Company and/or its Directors is as follows, (1) and (2) Mr. Sudhir Valia – INR 50,000 and Mr. Sailesh Desai – INR 50,000 (3) and (4) each, Sun Pharmaceutical Industries Limited – INR 50,000; Mr. Dilip Shanghvi – INR 50,000; Mr. Sailesh Desai – INR 50,000; Mr. Sudhir Valia – INR 50,000
c)	Date of receipt of direction or order, including any ad-interim or interim orders or any other communication from the authority	November 5, 2024
d)	Details of the violation(s)/contravention(s) Committed or alleged to be committed	This matter pertains to the earlier investigation carried out by SEBI, in which a Settlement was reached with SEBI in February 2021 without admission or denial of guilt; however, the Ministry of Corporate Affairs also initiated an investigation in parallel in 2019. The adjudication orders pertain to the following technical/procedural matters. (1) and (2) directorships in foreign group companies not provided in Form DIR-2 issued in FY 2018-19. (3) and (4) details of directors' shareholding in other companies not provided in Form DIR-12 in FY 2017-18 and FY 2018-19.
e)	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the Company's financial, operation or other activities.